SARS-CoV-2 testing among patients and healthcare professionals in an HIV outpatient clinic in Brazil

Página do item simplificado
dc.contributor.authorMatsuda, Elaine Monteiro
dc.contributor.authorde Oliveira, Isabela Penteriche
dc.contributor.authorde Campos, Ivana Barros
dc.contributor.authorAhagon, Cintia Mayumi
dc.contributor.authorCastejon, Marcia Jorge
dc.contributor.authorSilva, Valeria Oliveira
dc.contributor.authorManzoni, Fernanda Matsuda
dc.contributor.authorLópez-Lopes, Giselle Ibette
dc.contributor.authorBrígido, Luís Fernando de Macedo
dc.contributor.institutionSecretaria Municipal de Saúde
dc.contributor.institutionUniversidade do Estado de São Paulo
dc.contributor.institutionCentro de Laboratório Regional Santo André
dc.contributor.institutionCentro de Virologia
dc.contributor.institutionCentro de Imunologia
dc.date.accessioned2022-04-29T08:46:35Z
dc.date.available2022-04-29T08:46:35Z
dc.date.issued2022-01-01
dc.description.abstractThe COVID-19 pandemic in Brazil has been marked by high infection and death rates. The immune response generated by current vaccination might be influenced by previous natural infection, and baseline estimates may help in the evaluation of vaccine-induced serological response. We evaluated previous SARS-CoV-2 testing (RT-PCR), and performed rapid diagnostic tests (RDT) and high throughput electrochemiluminescence immunoassay (ECLIA) before vaccination among people living with HIV (PLWH), users of antiretroviral prophylaxis (PrEP/PEP), and healthcare professionals in an HIV outpatient clinic (HCP-HC). RDT was positive in 25.7% (95% CI: 19-33%) overall, 31.3% (95% CI: 18-45%) among PLWH, 23.7% (95% CI: 14-34%) in PrEP/PEP users and 21.4% (95% CI: 05-28%) in HCP-HC (p=0.548). Diagnostic RT-PCR testing was very limited, even for symptomatic individuals, and whereas all HCP-HC had one test perfomed, only 35% of the patients (PREP/ PEP/PLWH) were tested (p<0.0001). Adequate monitoring of post-vaccination humoral response and breakthrough infections including those in asymptomatic cases are warranted, especially in immunologically compromised individuals.en
dc.description.affiliationSecretaria Municipal de Saúde, São Paulo
dc.description.affiliationUniversidade do Estado de São Paulo, Campus Botucatu, São Paulo
dc.description.affiliationInstituto Adolfo Lutz Centro de Laboratório Regional Santo André, São Paulo
dc.description.affiliationInstituto Adolfo Lutz Centro de Virologia, São Paulo
dc.description.affiliationInstituto Adolfo Lutz Centro de Imunologia, São Paulo
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipIdCNPq: 24/2019-442776/2019-5
dc.identifierhttp://dx.doi.org/10.1590/S1678-9946202264003
dc.identifier.citationRevista do Instituto de Medicina Tropical de Sao Paulo, v. 64.
dc.identifier.doi10.1590/S1678-9946202264003
dc.identifier.issn1678-9946
dc.identifier.issn0036-4665
dc.identifier.scopus2-s2.0-85124275676
dc.identifier.urihttp://hdl.handle.net/11449/231615
dc.language.isoeng
dc.relation.ispartofRevista do Instituto de Medicina Tropical de Sao Paulo
dc.sourceScopus
dc.subjectHealth care personals
dc.subjectHIV
dc.subjectPEP
dc.subjectPrEP
dc.subjectPrevalence
dc.subjectSARS-CoV-2
dc.titleSARS-CoV-2 testing among patients and healthcare professionals in an HIV outpatient clinic in Brazilen
dc.typeArtigo

Arquivos

Coleções

Artigos - Microbiologia e Imunologia - IBB